Compare Gilead Sciences, Inc. (GILD) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Stanley Black & Decker, Inc. — how do they compare? Gilead Sciences, Inc. trades at $135.78 (market cap $168.35B), while Stanley Black & Decker, Inc. trades at $102.67 (market cap $15.71B). The key difference: Gilead Sciences, Inc. is far larger — about 10.7× Stanley Black & Decker, Inc.'s market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.23%). Which is the better fit depends on your goals.
| GILD | SWK | |
|---|---|---|
Market Cap | $168.35B | $15.71B |
Sector | Health | — |
52-Week High | $155.80 | $104.00 |
52-Week Low | $110.56 | $62.12 |
Enterprise Value | $191.42B | $19.87B |
Dividend Yield | 2.42% | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
SWK trades at $102.9, up 0.25% today, with a bullish technical signal from moving averages but overbought RSI levels near 80. The company reported strong Q2 2026 earnings, beating EPS estimates with $1.57 versus $1.21 expected, and raised full-year guidance. Revenue for 2025 was $15.13B, with net income margin improving to 2.65%. Recent news highlights a $1 billion U.S. investment plan and institutional buying, supporting positive momentum.
The outlook is cautiously optimistic, with earnings growth and margin expansion driving potential upside, though the stock trades above the consensus price target of $93.67. Risks include debt levels and economic sensitivity, but institutional accumulation and dividend stability offer support. The current price near resistance at $105 may limit near-term gains despite fundamental improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
